Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2301
Ampco-Pittsburgh
AP
$195M
| $1.61M | ﹤0.01% |
523,024
+22,400
| +4% | +$72K |
|
|
RUTH
2302
DELISTED
Ruth's Hospitality Group, Inc.
RUTH
| $1.6M | ﹤0.01% |
196,400
+91,100
| +87% | +$794K |
|
2303
Trimble
TRMB
$13.5B
| $1.6M | ﹤0.01% |
+37,000
| New | +$1.39M |
|
|
TCFC
2304
DELISTED
The Community Financial Corporation Common Stock
TCFC
| $1.6M | ﹤0.01% |
65,468
-3,719
| -5% | -$81.8K |
|
|
GOLD
2305
Gold.com Inc
GOLD
$1.28B
| $1.6M | ﹤0.01% |
167,584
+110,984
| +196% | +$876K |
|
|
MTL
2306
DELISTED
Mechel PAO American Depository Shares, each representing two ordinary shares (ADSs)
MTL
| $1.59M | ﹤0.01% |
925,270
+94,900
| +11% | +$166K |
|
2307
Full House Resorts
FLL
$82.8M
| $1.59M | ﹤0.01% |
1,192,590
+29,999
| +3% | +$45.5K |
|
2308
State Street SPDR S&P China ETF
GXC
$470M
| $1.58M | ﹤0.01% |
+15,100
| New | +$1.48M |
|
|
BCLI
2309
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $1.58M | ﹤0.01% |
9,416
-29,027
| -76% | -$3.13M |
|
2310
Dianthus Therapeutics
DNTH
$6.47B
| $1.58M | ﹤0.01% |
13,144
+2,535
| +24% | +$357K |
|
2311
Assembly Biosciences
ASMB
$649M
| $1.58M | ﹤0.01% |
5,637
+1,317
| +30% | +$307K |
|
|
IFLN
2312
Invesco Bloomberg Enhanced Fallen Angels ETF
IFLN
$307M
| $1.57M | ﹤0.01% |
86,809
+62,309
| +254% | +$1.1M |
|
2313
Grupo SIMEC
SIM
$4.68B
| $1.57M | ﹤0.01% |
255,400
+600
| +0.2% | +$3.99K |
|
2314
Norwood Financial Corp
NWFL
$375M
| $1.56M | ﹤0.01% |
62,875
+3,400
| +6% | +$80.7K |
|
2315
Canadian Pacific Kansas City
CP
$82.2B
| $1.56M | ﹤0.01% |
30,500
-318,500
| -91% | -$15.1M |
|
2316
Vince Holding Corp
VNCE
$80.6M
| $1.56M | ﹤0.01% |
280,452
-30,302
| -10% | -$168K |
|
2317
IDEAYA Biosciences
IDYA
$3.51B
| $1.55M | ﹤0.01% |
+109,100
| New | +$860K |
|
|
SLCT
2318
DELISTED
Select Bancorp, Inc.
SLCT
| $1.55M | ﹤0.01% |
190,375
+13,414
| +8% | +$101K |
|
2319
Fluor
FLR
$7.04B
| $1.55M | ﹤0.01% |
128,000
-241,400
| -65% | -$2.53M |
|
|
NEWR
2320
DELISTED
New Relic, Inc.
NEWR
| $1.54M | ﹤0.01% |
+22,400
| New | +$1.34M |
|
2321
Regency Centers
REG
$14B
| $1.54M | ﹤0.01% |
33,525
-1,064,570
| -97% | -$45M |
|
|
SVA
2322
DELISTED
Sinovac Biotech, Ltd
SVA
| $1.54M | ﹤0.01% |
2,375,841
| – | – |
|
2323
HF Sinclair
DINO
$16.6B
| $1.53M | ﹤0.01% |
52,582
-312,276
| -86% | -$9.28M |
|
|
AGFS
2324
DELISTED
AgroFresh Solutions Inc
AGFS
| $1.53M | ﹤0.01% |
506,433
+218,429
| +76% | +$541K |
|
2325
KORU Medical Systems
KRMD
$157M
| $1.53M | ﹤0.01% |
170,500
+67,578
| +66% | +$683K |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.